6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date:  For the month of [month year]
Oxford GlycoSciences Plc
(Registrant's Name)
The Forum, 86 Milton Park
Abingdon
United Kingdom OX14 4RY
(Registrant's Address)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F   Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes  No
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-






[Insert Press Release or text of report]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Oxford GlycoSciences Plc

By:
Name: John Ilett
Title: Company Secretary
Date:

EX-99

                  Company Oxford Glycosciences PLC
                  TIDMOGS
                  Headline Re Agreement
                  Released 07:01 19 Sep 2002
                  Number 3693B



For further information please contact:

      Oxford GlycoSciences Plc
      David Ebsworth, Chief Executive Officer
      Website: www.ogs.com
      Tel: +44 (0) 1235 208000


      Financial Dynamics
      UK Media and Investors
      Melanie Toyne-Sewell
      Sarah Mehanna Tel:
      +44 (0) 20 7831 3113


      US Media and Investors
      Leslie Wolf-Creutzfeldt
      Deborah Arden-Jones
      Tel: +1 - 212 850 5600


For Immediate Release


OGS and FDA to Evaluate Protein Markers
Predictive of Drug Toxicity

Oxford, UK, 19 September 2002 -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq:
OGSI) today announced that it has entered a Cooperative Research and
Development Agreement (CRADA) with the Center for Drug Evaluation and
Research of the US Food and Drug Administration (FDA).  The research
collaboration will aim to identify serum protein biomarkers that could be
useful across species during drug development for early prediction and
evaluation of drug‑induced toxicities to minimize risk of serious
adverse events in clinical trials as well as after drug approval.

Under the terms of the CRADA, titled "Development of Improved Biomarkers
for Early Detection of Myocardial Injury, Vascular Injury, and Liver
Injury", FDA researchers will initiate a programme to develop specific
models of drug-induced histopathologic injury to the myocardium, the
vasculature, and the liver and will produce biological samples suitable
for proteomics analysis.  The investigators at OGS will use industrial
scale proteomics technology to analyse those samples and identify serum
markers indicative of specific toxic responses.

David Ebsworth, Ph.D., Chief Executive Officer of OGS, commented:
"Drug-induced toxicity is an increasing concern of regulatory authorities
and the pharmaceutical industry in general.  For example, drug-induced
damage to the liver is the most common type of toxicity that results in a
treatment being withdrawn from clinical trials or from further marketing.
Similarly, cardiotoxicity is a frequent occurrence in patients undergoing
cancer chemotherapy.  However, the currently available biomarkers for these
common types of drug-induced toxicities have limited sensitivity or
predictive value."

He added: "We believe that this research collaboration with the FDA offers
great potential for discovering better biomarkers that may have a
significant impact on the research and development of safer drugs."

Frank Sistare, Ph.D., Director of the Division of Applied Pharmacology
Research at the Center for Drug Evaluation and Research at the FDA,
commented: "We have been relying on the same set of clinical chemistry
endpoints for routine animal toxicity testing and clinical trial safety
monitoring for over 25 years.  The proteomic tools available today are
empowering us to tap into the wealth of genome sequence information to
discover and carefully investigate associations of thousands of proteins
with drug-induced toxicities that are now not easily monitored."



About OGS

OGS has developed a patented technology platform in the emerging field of
proteomics, the comprehensive study of proteins, integrating proteomics
with genomics to create an innovative drug discovery platform.  OGS'
proteomics collaborations with major pharmaceutical and biotechnology
companies include Bayer, Pioneer Hi-Bred/DuPont, GlaxoSmithKline and
Pfizer.  OGS has drug discovery and development alliances with Medarex,
NeoGenesis and BioInvent and technology development collaborations with
Applera, Cambridge Antibody Technology, Packard BioScience and The
Institute for Systems Biology. OGS has also entered into a joint venture,
Confirmant Limited, to develop the Protein Atlas of the Human Genome.

OGS has drug research discovery programmes in central nervous system,
cancer, infectious disease and glycosphingolipid storage disorders (GSLDs).

In July 2002, OGS' lead compound, ZavescaTM, received a positive opinion
from the Committee for Proprietary Medicinal Products, recommending
approval of the drug in Europe for the treatment of mild to moderate type
1 Gaucher disease in patients for whom enzyme replacement therapy is
unsuitable. Zavesca is undergoing further clinical investigations in
several GLSDs.

About CRADAs

A CRADA is a written agreement between a private company and a government
agency to work together on a project. By entering into a CRADA, the
Federal government and non-Federal partners can optimise their resources
and cost-effectively perform research by sharing the costs of this
research. The collaborating partner agrees to provide funds, personnel,
services, facilities, equipment or other resources needed to conduct a
specific research or development effort while the Federal government
agrees to provide similar resources but not funds directly to the partner.

This release contains forward-looking statements, such as the commercial
potential and success of OGS' collaborations and drug candidates. Factors
that could cause actual results to vary significantly from those expressed
or implied by these and other forward-looking statements include the
success of OGS' research and development strategies, the validity of
its technologies and intellectual property position and strategies,
the medical conclusions on which Zavesca (INN:miglustat) is based and
uncertainties related to the regulatory process.
END

EX-99

                  Company Oxford Glycosciences PLC
                  TIDMOGS
                  Headline Bayer Collaboration
                  Released 07:00 23 Sep 2002
                  Number 4885B






For further information please contact:

Oxford GlycoSciences Plc
Dr David Ebsworth, Chief Executive Officer
Tel: +44 (0)1235 208000
Website: www.ogs.com

UK: Financial Dynamics
Melanie Toyne-Sewell/Sarah Mehanna
Tel: +44 (0) 20 7831 3113

USA: Financial Dynamics
Contact: Leslie Wolf-Creutzfeldt/
Deborah Arden Jones
Tel: +1 212 497 9202

For Immediate Release

OGS Announces Acceptance of Validated Protein Targets For Respiratory
Disease By Bayer

Oxford, UK, 23 September 2002 -- Oxford GlycoSciences Plc (LSE: OGS,
Nasdaq: OGSI) today announced that Bayer AG has accepted the first protein
targets resulting from an ongoing research collaboration. OGS' proteomics
technology has been used for the identification of clinically valid
therapeutic targets and biomarkers in the areas of asthma and Chronic
Obstructive Pulmonary Disease (COPD) meeting Bayer's stringent validation
requirements.

Using clinical samples provided by Bayer, OGS has built a human pulmonary
disease protein expression database and identified a series of clinically
valid therapeutic targets against which drugs will be developed for patients
suffering from either disease.  The targets will now go into screening for
the discovery of potential therapeutic drugs.

Acceptance of these targets is a landmark in the OGS/Bayer agreement and
triggers an undisclosed milestone payment.

The original collaboration was initiated in March 2000 and extended by
mutual agreement in December 2001.  Under the terms of the agreement, Bayer
has committed programme funding to OGS and agreed to pay performance related
milestones payments as well as royalties to OGS on products developed by
Bayer from the collaboration.  The parties will jointly own intellectual
property arising from the research and OGS will have exclusive rights to
commercialise diagnostic markers arising from the collaboration.

'The acceptance of the targets is both a milestone under the agreement and
a landmark for the proteomics platform,' said Dr David Ebsworth, Chief
Executive Officer of OGS. 'Bayer's acceptance of these targets validates
our on-going investment in our proteomics platform and our belief that
proteomics can play a vital role in helping to accelerate drug discovery
and development programmes.'

###

Notes to Editors

OGS has developed a patented technology platform in the emerging field of
proteomics, the comprehensive study of proteins, integrating proteomics with
genomics to create an innovative drug discovery platform.  OGS' proteomics
collaborations with major pharmaceutical and biotechnology companies include
Bayer, Pioneer Hi-Bred/DuPont, GlaxoSmithKline and Pfizer.  OGS has drug
discovery and development alliances with Medarex, NeoGenesis and BioInvent
and technology development collaborations with Applera, Cambridge Antibody
Technology, Packard BioScience and The Institute for Systems Biology.  OGS
has also entered into a joint venture, Confirmant Limited, to develop the
Protein Atlas of the Human GenomeTM.

OGS has drug research discovery programmes in central nervous system,
cancer, infectious disease and glycosphingolipid (GSL) storage disorders.

In July 2002, OGS' lead compound, ZavescaTM, received a positive opinion
from the Committee for Proprietary Medicinal Products, recommending approval
of the drug in Europe for the treatment of mild to moderate type 1 Gaucher
disease in patients for whom enzyme replacement therapy is unsuitable.
Pending final review by the European Commission, ZavescaTM is an
investigational drug and has not received approval for marketing in any
country.  Zavesca is undergoing further clinical investigations in several
GSL storage disorders.

This release contains forward-looking statements, such as the commercial
potential and success of OGS' collaborations and drug candidates. Factors
that could cause actual results to vary significantly from those expressed
or implied by these and other forward-looking statements include the success
of OGS'research and development strategies, the validity of its technologies
and intellectual property position and strategies, the medical conclusions
on which Zavesca (INN:miglustat) is based and uncertainties related to the
regulatory process.

EX-99

For further information please contact:

Oxford GlycoSciences Plc
David Ebsworth, PhD, Chief Executive Officer
Tel: +44 (0) 1235 208 000
Website: www.ogs.com

Financial Dynamics
UK Media and Investors
Tim Spratt
Melanie Toyne-Sewell
Tel: +44 (0) 20 7831 3113

US Media and Investors
Leslie Wolf-Creutzfeldt
Deborah Ardern Jones
Tel: +1 212 850 5626
For Immediate Release

Oxford GlycoSciences Plc
Interim Results for the six months ending 30 June 2002

Oxford, UK, 26 September 2002 -- Oxford GlycoSciences Plc
(LSE: OGS.L, Nasdaq:
OGSI) today announced its interim results for the six months
ending 30 June
2002.

Operational Review

Organisational
- -          Appointment of Dr. David Ebsworth as Chief
Executive Officer
- -          Completion of strategic review of OGS operations
- -          Implementation of cost control efforts to reduce
burn-rate
- -          Divisionalisation of OGS into three business units
 Proteomics,
Inherited Storage Disorders and Oncology
- -          Appointment of Denis Mulhall as new CFO (see
separate announcement
today)

Commercial
- -          Positive CPMP opinion recommending EU approval for
Zavesca(TM)
- -          Marketing collaboration for Zavesca in EU signed
with Actelion
representing significant cost savings, equitable profit share
and faster route
to market for Zavesca
- -          Medarex collaboration progressing well and on
target to file an IND
for MDX-OGS 001
in Q2 2003
- -          Three year collaboration signed with BioInvent to
identify, develop,
manufacture and commercialise novel therapeutic antibodies
- -          First licence issued to GeneProt to operate under
OGS' proteomics
patents
- -          New collaboration with Cystic Fibrosis Foundation
Therapeutics Inc to
discover and validate serum biomarkers of cystic fibrosis
- -          Acceptance of the first clinically valid protein
targets by Bayer
using OGS' core proteomics technologies
- -          Cooperative Research and Development Agreement
(CRADA) signed with
FDA to identify serum biomarkers for the early prediction and
evaluation of drug
induced toxicities

Financial review
- -          Revenue of GBP5.8m for the six months to 30 June
2002 (H1 2001: GBP8.7m)
- -          Loss for the period was GBP19.5m (H1 2001:
GBP7.2m), reflecting the
expansion of OGS' drug discovery programmes with NeoGenesis
and BioInvent, and
manufacturing costs associated with Zavesca launch
- -          Cash balance at 30 June 2002 of GBP153.4m (at 31
December 2001:
GBP176.6m)

Commenting on the results and strategic review, Dr David
Ebsworth, CEO of OGS,
said: "Following the strategic review and the cost cutting
initiative, OGS has a
renewed direction.  We see OGS becoming an R&D based
pharmaceutical company with
a focus on products for oncology and inherited storage
disorders, supported by
world-class proteomics.  We are confident that this new
organisation will
provide greater transparency and form the basis for an
improvement in OGS'
performance, a reduction in cash burn and a restoration of
shareholder value."

- - Ends -

Notes to Editors
OGS has developed a patented technology platform in the
emerging field of
proteomics, the comprehensive study of proteins, integrating
proteomics with
genomics to create an innovative drug discovery platform.
OGS' proteomics
collaborations with major pharmaceutical and biotechnology
companies include
Bayer, Pioneer Hi-Bred/DuPont, GlaxoSmithKline and Pfizer.
OGS has drug
discovery and development alliances with Medarex, NeoGenesis
and BioInvent and
technology development collaborations with Applera, Cambridge
Antibody
Technology, Packard BioScience and The Institute for Systems
Biology. OGS has
also entered into a joint venture, Confirmant Limited, to
develop the Protein
Atlas of the Human Genome(TM).

OGS has drug research discovery programmes in central nervous
system, cancer,
infectious disease and glycosphingolipid storage disorders.

In July 2002, OGS' lead compound, Zavesca, received a positive
opinion from the
Committee for Proprietary Medicinal Products, recommending
approval of the drug
in Europe for the treatment of mild to moderate type 1 Gaucher
Disease in
patients for whom enzyme replacement therapy is unsuitable.
Pending final review
by the European Commission, Zavesca is an investigational drug
and has not
received approval for marketing in any country. Zavesca is
undergoing further
clinical investigations in several glycosphingolipid storage
disorders.

This release contains forward-looking statements, such as the
commercial
potential and success of OGS' collaborations and drug
candidates.  Factors that
could cause actual results to vary significantly from those
expressed or implied
by these and other forward-looking statements include the
success of OGS'
research and development strategies, the validity of its
technologies and
intellectual property position and strategies, the medical
conclusions on which
Zavesca (INN: miglustat) is based and uncertainties related to
the regulatory
process.


EXTRACTS FROM CHAIRMAN AND CHIEF EXECUTIVE'S INTERIM STATEMENT

INTRODUCTION
During the period, Michael Kranda, who has served the Company
as Chief Executive
Officer since 1996, announced his decision to resign from the
Company for
personal reasons.  We are delighted to welcome David Ebsworth
as his successor.
David became Chief Executive Officer on 1 July following a
successful career at
Bayer where he was Global Head of Pharmaceuticals.  He has
already moved the
Company forward, implementing significant changes to control
costs, improve
focus and build the potential for long-term profitability.
His management as
well as his sales and marketing experience have also been
invaluable in
determining the right course to launch Zavesca in Europe.

STRATEGIC REVIEW
Upon David Ebsworth's appointment, the senior management has
taken the
opportunity to review the operations, structure and cost base
of the Company.

The review highlighted the core competencies of the Company.
We have a leading
technology base in our world-class proteomics platform,
several molecules with
high potential in the fields of cancer and inherited storage
disorders
approaching the clinic and, closest to launch, Zavesca for
which we anticipate
European approval by the end of the year.  We also have a
solid cash position,
with GBP153.4m at 30 June 2002.

The Company has taken immediate action on the cost base.  In
light of the delays
in the approval of Zavesca in the USA, one of the first
decisions was to reduce
our cost base and burn-rate by closing our Bridgewater, New
Jersey facility. As
part of that process, Don DeGolyer, who was appointed to the
Board during the
period, resigned from the Company.  We have also carried out a
review of our UK
operations and made some selective redundancies and
restructured and streamlined
some of our existing alliances.

Going forward, our objective is to focus on those parts of our
business that
will enhance shareholder value in the shortest possible time.
To achieve this,
the Company will be reorganised into three separate business
units: Inherited
Storage Disorders (ISD), Proteomics and Oncology. ISD and
Oncology will each
form the core of our research and product development
activities with support
from Proteomics. In this way, we intend to increase
transparency, responsibility
and accountability.

From January 2003, these distinct business units will report
separately. Their
aim will be to leverage the internal expertise in the Company
and the external
expertise of our partners. The objective is to maximise
progress and value
creation, while controlling costs and minimising cash burn.
Financially,
Proteomics will aim to achieve profitability in 2003 and ISD
in 2005.  Oncology
will be the main area of strategic investment, with the major
allocation of OGS
cash.  This will fund the development of high quality oncology
products, both
from the development of our existing in-house portfolio and
from strategic
acquisitions of products and, where appropriate, companies.
Our aim for the
Oncology division is for it to attract the best clinical
oncology programmes in
the industry, enabling us to expand our clinical development
pipeline.

OPERATIONAL REVIEW

- -                   Proteomics

From the strategic review, it is clear that the potential of
our world-class
proteomics research is beginning to be realised. During the
period, a number of
our existing collaborations were extended and significant new
collaborations
were signed.

- - Extended collaborations
We have extended our proteomics collaborations with Pfizer to
identify
biomarkers for Alzheimer's disease and atherosclerosis and
with Bayer to
identify therapeutic targets for asthma and Chronic
Obstructive Pulmonary
Disease (COPD).  Bayer has recently accepted targets under its
collaboration,
which means that our targets have met stringent validation
criteria and will go
directly into screening for discovery of potential therapeutic
drugs.  We have
also achieved external validation of our investment in
intellectual property
through the issuance of the first licence to our core
proteomics patents and
technologies to GeneProt.

- - New collaborations
A new proteomics initiative was signed with the Cystic
Fibrosis Foundation
Therapeutics Inc to discover and validate serum biomarkers of
Cystic Fibrosis
and associated pulmonary complications. More recently, OGS
entered into a
Cooperative Research and Development Agreement (CRADA) with
the Center for Drug
Evaluation and Research of the US Food and Drug Administration
(FDA).  The
research collaboration will aim to identify serum protein
biomarkers that could
be useful across species during drug development for early
prediction and
evaluation of drug-induced toxicities.

- - Confirmant
Confirmant is OGS' 50:50 joint venture with Marconi to develop
a Protein Atlas
using OGS' core proteomics technologies. Discussions are on-
going with Marconi
and other companies to ensure value creation.  We continue to
adopt a
conservative approach to revenue recognition, whilst at the
same time fully
consolidating the losses.

Going forward, the strategy for Proteomics is to further
extend its commercial
relationships, commercialise its existing intellectual
property and create new
product offerings so that it rapidly achieves profitability.
It is forecast to
continue to grow its revenues in the current year to an
estimated GBP14m by
year-end, up from GBP13.4m in the previous year. As a result
of recent proactive
cost control, we have reduced operating costs in this business
unit by 40%
(GBP4.7m) on an annualised basis.  With its reduced cost base
we believe the
Proteomics business unit will be able to compete effectively
for business not
previously available to it.  We are committed to achieving a
profitable
Proteomics business in 2003 and we will achieve this with a
tightly controlled
investment.

- -                   Inherited Storage Disorders (ISD)

In July, we received a positive opinion from the Committee for
Proprietary
Medicinal Products (CPMP) for recommendation of Zavesca, our
oral therapy
against type 1 Gaucher Disease, for approval by the European
Commission.  The
aim for ISD is to build a franchise around Zavesca.  It is our
goal to establish
a market presence in type 1 Gaucher Disease, to expand the
product label and
explore new previously untreatable indications.  In addition
to Zavesca, we have
a second product, OGT 923, which has shown promising results
in in vivo studies
and we expect it to enter the clinic by the end of 2002.

- - Zavesca Update
Following the CPMP's positive opinion, our priority is to
continue working with
the regulators to complete the final steps in the process to
achieve full
approval for the drug in Europe, which we expect to be by the
end of the year.
In conjunction with our Israeli marketing partner, Teva, we
plan to file Zavesca
in Israel before the year end.  With respect to the USA, OGS
had a meeting with
the FDA on 24 September and we expect additional guidance in
the near future.

In Europe, we plan to begin shortly a new dosing
schedule/switch trial with
Zavesca.  In Israel, IRB permission to recommence drug trials
was received in
July.  We plan to initiate an access protocol for those
patients that want to
continue to receive Zavesca at the end of clinical studies.
Our study OGT-918
005 is continuing at New York University.

A trial exploring Zavesca in Niemann-Pick type C has
commenced.  We expect
similar trials in type 3 Gaucher Disease and Late Onset Tay
Sachs to begin
recruiting in 2002.  These indications represent a potential
pool of some 2,000
additional patients for which there is no alternative therapy.

- - Actelion Partnership
In July, we announced a European marketing and distribution
partnership with
Actelion for Zavesca.  Under the terms of this partnership,
Zavesca will be
marketed in the EU by Actelion.  This is a five year agreement
that provides
excellent economics for OGS and offers substantial cost
savings and risk
reduction when compared to the alternative of building our own
infrastructure.
It also offers a quicker route to market for Zavesca.

- - OGT 923
Preclinical development of OGT 923, an analogue of Zavesca, is
in its final
stages and we are on target for a first dose in man by the end
of 2002.   In
vivo studies indicate that OGT 923 may offer a number of
advantages, such as the
ability to offer higher doses, increased efficacy and better
tolerability.  The
higher doses may enable OGT 923 to have an impact on inherited
storage disorders
that affect the central nervous system.

Longer term, ISD will focus on launching and developing the
Zavesca franchise
and OGT 923.  We have also set a clear financial goal of
achieving profitability
in 2005 and a tightly controlled investment has been set to
help achieve this.

- -                   Oncology Business Unit

We believe that by having a separate Oncology business unit,
we will be able to
exploit the enormous potential of targets derived from our
proteomics research
to discover novel modes of action and to leverage our existing
drug discovery
partnerships.  We expect to have our first drug from our own
R&D efforts in man
during 2003.

- - MDX-OGS 001 (Heparanase 1 antibody)
Our collaboration with Medarex is progressing well.  The
efforts exerted by the
research and development teams are showing results and we
anticipate that an IND
for an oncology indication will be filed for MDX-OGS 001 in Q2
2003.

- - OGT 2492
We have discontinued preclinical development of our first
anti-heparanase new
chemical entity (NCE), OGT 2492 after inconclusive preclinical
results. We are
currently evaluating various back-up compounds and expect to
bring the chosen
candidate into the clinic by the end of 2004.

- - Imino Sugars
From our imino sugar research, we have identified a number of
compounds with
anti-cancer activity.  A lead compound, OGT 2378 is being
explored in
preclinical oncology models and we have a target IND date of
Q1 2004.

- - BioInvent
In March, we entered into a second collaboration in monoclonal
antibodies, with
BioInvent, a Swedish biotechnology company.  BioInvent is a
leading player in
phage display technologies, giving OGS an additional means of
discovering
antibody therapies.  Most of the ensuing antibody discoveries
will be
wholly-owned by OGS.  As part of this collaboration, OGS has
invested $5m in
BioInvent.

Oncology will become an increasing focus for OGS and the major
portion of OGS
cash will be allocated to funding the development of high
quality oncology
products.  Operationally the Oncology business unit will focus
on the
development of OGS' current pipeline, with strategic
acquisitions of products
and, where appropriate, companies to fill the gap in our
clinical pipeline.

FINANCIAL REVIEW
In the first half of 2002, the Group reported revenue of
GBP5.8m (H1 2001: GBP8.7m).
The difference in revenue is partly due to the initial
GBP3.25m recognised in the
preceding year resulting from the Confirmant joint venture.
There was a net
loss of GBP19.5m (H1 2001: GBP7.2m), which is primarily due to
an increase in net
operating costs to GBP28.8m (H1 2001: GBP22.7m) reflecting the
expansion of OGS'
drug discovery programmes with NeoGenesis and BioInvent, and
the manufacturing
costs associated with the Zavesca launch in Europe.  There was
a tax credit of
GBP1.9m (H1 2001: GBP1.4m) in respect of amounts recoverable
under the R&D tax
credit scheme.

Specific cost saving measures have been implemented to reduce
cash burn,
including a reduction in headcount, which will incur a one-off
charge of GBP1.1m
to the Profit and Loss Account in the second half of the year.
On an annualised
basis, there will be a saving of approximately GBP3.5m with
effect from the end of
the third quarter of which GBP2.4m relates to Proteomics and
is included in the
GBP4.7m savings identified in the Operational Review.

Cash balances at the end of June were GBP153.4m (at 31
December 2001: GBP176.6m).

MANAGEMENT
As mentioned above, in light of Michael Kranda's resignation
as CEO for personal
reasons, David Ebsworth, formerly Global Head of
Pharmaceuticals, of Bayer, has
been appointed in his place.  We have also appointed Denis
Mulhall as Chief
Financial Officer.  He is a senior executive with a strong
international
background in finance and operations and will be taking over
from Stephen Parker
who will be leaving the Company with immediate effect. On
closure of the US
office, Don DeGolyer, who was appointed to the Board during
the period, resigned
from the Board and the Company.

OUTLOOK
After a comprehensive strategic review, our strategy is to
become an R&D based
pharmaceutical company with a focus on products for oncology
and inherited
storage disorders, supported by world-class proteomics.  We
are confident that
this new organisation will provide greater transparency and
form the basis for
an improvement in OGS' performance, a reduction in cash burn
and a restoration
of shareholder value.

Over the last six months the global stock markets have proved
challenging for
companies in all sectors and OGS has been affected along with
many other
biotechnology companies.  We are grateful for the continued
support of our
shareholders along with the great commitment and efforts of
our staff during the
period and look forward to the improved development of the
Group, guided by a
clear strategy and regained momentum.

      G. Kirk Raab
      Chairman
       David R. Ebsworth, PhD
      Chief Executive Officer



Unaudited Consolidated Profit and Loss Account




      NotesHalf year
      Ended
      30.06.02
      GBP'000
      ______Half year
      Ended
      30.06.01
      GBP'000
      ______Year
      Ended
      31.12.01
      GBP'000
      ______

      Turnover2,35,7808,71213,376
      Net operating costs (28,767)(22,879)(49,396)

      Operating loss (22,987)(14,167)(36,020)
      Share of joint venture loss3(1,641)-(2,007)
      Profit on disposal -10982

      Loss on ordinary activities before interest and taxation
      (24,628)(14,058)(37,945)
      Net interest receivable 3,2565,4139,733

      Loss on ordinary activities before taxation
(21,372)(8,645)(28,212)
      Tax on loss on ordinary activities 1,8531,4132,864

      Loss for the period (19,519)(7,232)(25,348)

      Loss per ordinary 5p share
      - basic and diluted4(35.11p)(13.25p)(46.04p)


The Group has no recognised gains and losses other than the
losses above and
therefore no separate statement of total recognised gains and
losses has been
presented.

There is no difference between the losses on ordinary
activities before taxation
and the losses for the periods stated above, and their
historical cost
equivalents.

Unaudited Group Balance Sheet




      NotesHalf year
      Ended
      30.06.02
      GBP'000
      ______Half year
      Ended
      30.06.01
      GBP'000
      ______Year
      Ended
      31.12.01
      GBP'000
      ______
      Fixed assets
      Tangible assets 14,80014,08914,221

      Investments
      Investments in joint venture - share of gross assets
11,87415,00014,679
      Investment in joint venture - share of gross liabilities
(522)-(1,686)
      Investment in joint venture - provision for unrealised
profit
      (2,162)(3,250)(2,708)
       39,19011,75010,285

      Other investments57,779-4,251

        31,76925,83928,757
      Current assets
      Stock  321251346
      Debtors  10,1169,8379,626
      Cash at bank and in hand 153,376195,872176,618
        163,813205,960186,590

      Creditors: amounts falling due within one year
(18,622)(15,836)(18,250)

      Net current assets 145,191190,124168,340

      Total assets less current liabilities
176,960215,963197,097

      Creditors: amounts falling due after more than one year
      (1,614)(3,640)(2,399)
      Provisions for liabilities and charges -(73)(87)

      Net assets 175,346212,250194,611

      Capital and reserves
      Share capital 2,7852,7612,778
      Share premium account 276,197275,490275,950
      Capital reserve 11,10711,10711,107
      Profit and loss account (deficit)
(114,743)(77,108)(95,224)

      Equity shareholders' funds6175,346212,250194,611


The financial information contained in this interim report
does not constitute
statutory accounts as defined in section 240 of the Companies
Act 1985.  This
statement of half year results will be sent to all
shareholders.  Copies are
available to members of the public at the Group's registered
office shown at the
back of this report.

The comparative figures for the year ended 31 December 2001
have been extracted
from the Group's statutory financial statements for that
financial year.  Those
accounts carried an unquantified audit report and have been
filed with the
Registrar of Companies.

Unaudited Consolidated Cash Flow Statement




      NotesHalf year
      Ended
      30.06.02
      GBP'000
      ______Half year
      Ended
      30.06.01
      GBP'000
      ______Year
      Ended
      31.12.01
      GBP'000
      ______

      Net cash outflow from operating
activitiesA(22,379)(3,649)(22,164)

      Returns on investments and servicing of finance
4,6773,4379,042
      Taxation 1,281--
      Purchases of tangible fixed assets (3,547)(3,011)(5,306)
      Purchases of fixed asset investments
(3,528)(15,000)(19,251)
      Disposals - cash consideration -115122

      Net cash outflow before management
      of liquid resources and financing
(23,496)(18,108)(37,557)

      Management of liquid resources 32,10423,58539,480
      Financing 25410,08810,283

      Increase in net cashB8,86215,56512,206

      A Reconciliation of operating loss to net cash outflow
from operating
      activities

      Operating loss (22,987)(14,167)(36,020)

      Depreciation charges 2,4762,0014,418
      Decrease/ (increase) in stock 25(47)(170)
      (Increase)/ decrease in debtors (1,339)(344)34
      (Decrease)/ increase in deferred income
(1,585)5,7216,815
      Increase in creditors 1,0313,1872,759
        60810,51813,856

      Net cash outflow from operating activities
(22,379)(3,649)(22,164)

      B Reconciliation of net cash flow to movement
      in net funds

      Increase in cash in the period 8,86215,56512,206

      Cash inflow from movement in liquid resources
(32,104)(23,585)(39,480)

      Movement in net funds in the period
(23,242)(8,020)(27,274)

      Net funds at commencement of the period
176,618203,892203,892

      Net funds at the end of the period7153,376195,872176,618


Notes to the Accounts

1.      Accounting Policies
The interim financial statements have been prepared on the
basis of the
accounting policies set out in the Group's 2001 statutory
accounts.  The
statements were approved by a duly appointed and authorised
committee of the
Board of Directors on 25 September 2002.

2.      Segmental Information
The geographical analysis of turnover, all arising in the UK,
by destination is
as follows:

       Half year
      Ended
      30.06.02
      GBP'000
      ______Half year
      Ended
      30.06.01
      GBP'000
      ______Year
      Ended
      31.12.01
      GBP'000
      ______

      United Kingdom1,9463,2605,422
      Continental Europe8665971,180
      USA and Canada2,9154,8536,772
      Rest of the World5322

       5,7808,71213,376


Details of turnover from Confirmant, a joint venture owned by
OGS and Marconi,
are given in
note 3.

3.      Interest in joint venture
In June 2001, OGS formed a joint venture with Marconi, called
Confirmant
Limited, which will provide database services to
pharmaceutical and
biotechnology companies.

As at 30 June 2002, there is a provision for unrealised
profit, GBP2.2 million,
representing revenue from the sale of marketing rights and
data analysis
software to Confirmant.  This amount will be released over the
life of the
assets to which it relates.  Sales by OGS to Confirmant during
the period ended
30 June 2002 amounted to GBP1.9 million (2001: GBP3.3
million).

4.      Losses per share
The basic loss per share is calculated by dividing the loss
attributable to
ordinary shareholders of GBP19.5 million (2001: GBP7.2
million) by the weighted
average number of ordinary shares in issue during the period,
55.6 million
(2001: 54.6 million).

For diluted loss per share, the weighted average number of
ordinary shares in
issue is adjusted to assume the exercise of all options which
would be
potentially dilutive.  There is no difference between the
basic and diluted loss
per share.

5.      Other investments

       BioInvent
      International
      AB
      GBP'000
      ______NeoGenesis
      Pharmaceuticals
      Inc
      GBP'000
      ______

      Total
      GBP'000
      ______
      Cost:
      At 1 January 2002 -4,2514,251
      Additions 3,528-3,528
      At 30 June 20023,5284,2517,779
      Provisions:
      At 1 January 2002 and 30 June 2002---
      Net book value:
      At 30 June 20023,5284,2517,779
      Net book value:
      At 31 December 2001-4,2514,251


On 16 May 2002, OGS subscribed SEK52.0 million in cash at
SEK39.1 per share in
BioInvent International AB, as part of a research
collaboration.

At 30 June 2002, BioInvent International AB's share price was
SEK28.5 per share.
 However, this investment, and the investment in NeoGenesis
Pharmaceuticals Inc,
is not held for resale and management do not consider that any
permanent
diminution in value existed at that date.

6.      Reconciliation of movements in shareholders' funds

       Half year
      Ended
      30.06.02
      GBP'000
      ______Half year
      Ended
      30.06.01
      GBP'000
      ______Year
      Ended
      31.12.01
      GBP'000
      ______

      Loss for the period(19,519)(7,232)(25,348)
      New shares issued25410,09110,552
      Expenses of shares issued-(285)(269)
      Net (reduction in)/ addition to shareholders'
funds(19,265)2,574(15,065)
      Opening shareholders' funds194,611209,676209,676

      Closing shareholders' funds175,346212,250194,611



7.      Analysis of net funds

       31.12.01
      GBP'000
      ______Cash flow
      GBP'000
      ______30.06.02
      GBP'000
      ______

      Cash at bank and in hand14,0528,86222,914
      Bank deposits - liquid resources162,566(32,104)130,462
       176,618(23,242)153,376


Liquid resources represent all deposits with an original
maturity of between 24
hours and one year.  Cash includes cash in hand and deposits
of up to 24 hours
which are payable on demand.
END

EX-99

Oxford Glycosciences PLC
26 September 2002

For further information please contact:

Oxford GlycoSciences Plc
David Ebsworth, Ph.D, Chief Executive Officer
Tel: +44 (0) 1235 208000
Website: www.ogs.com

Financial Dynamics
UK Media and Investors
Tim Spratt / Melanie Toyne Sewell
Tel: +44 (0) 20 7831 3113

US Media and Investors
Leslie Wolf-Creutzfeldt / Deborah ArdernJones
Tel: +1 212 850 5600
For Immediate Release



                            Oxford GlycoSciences Plc
                                 BOARD CHANGES

Oxford, UK, 26 September 2002:  Oxford GlycoSciences Plc (LSE: OGS.L,
NASDAQ: OGSI) announced today the appointment of Denis Mulhall ACMA,
MBA as Chief Financial Officer and Finance Director. He will join the
Company and Board with immediate effect.

Denis, 51, was previously Chief Financial Officer of Metzeler Automotive
Profile Systems, a 1 billion euro revenue company which designs and
manufactures components for the major OEM's on a world wide basis. Prior
to joining Metzeler, Denis was the Chief Financial Officer and then
Chief Operating Officer of Berisford Plc. Denis joined Berisford in 1993
when it was a loss making shell company. The company was developed into
a FTSE 250 group through the acquisition and rationalisation of businesses
in the US, UK and Europe.

Commenting on the appointment, David Ebsworth, Ph.D., who joined Oxford
GlycoSciences as Chief Executive on 1 July, said: 'Denis brings
considerable financial and management experience to Oxford GlycoSciences
at an important stage of the Company's development. He has an international
background of reorganising and refocusing companies, in addition to
undertaking transactions. This is a skill set which we expect will be of
considerable benefit to the Group.'

Kirk Raab, Chairman of Oxford GlycoSciences Plc, added: 'I believe Denis
will be an important member of David's team and an excellent addition to
our strong Board of Directors.'

Stephen Parker has resigned from the Company's Board of Directors with
immediate effect, in order to pursue other interests.  The Board thanks
Stephen for his contribution and wishes him well for the future.

In accordance with paragraph 16.4 of the Listing Rules, no further details
regarding Mr. Mulhall are required to be disclosed under paragraph
6.F.2(b) to (g).  Mr. Mulhall is a non-executive director of RingProp plc.

EX-99

      Announcement Details
      Oxford Glycosciences PLCDirector Shareholding  10:36 27 Sep 02



      Full Announcement Text




      Directors' Shareholdings
      Puchases of shares in the Company have recently been made, as
      follows:
      (a) On 26 September 2002, Dr David Ebsworth acquired 5,000 shares
      at a price of 155p. This comprises Dr Ebsworth's entire holding and
      represents approximately 0.008% of the Company's issued share
      capital; and
      (b) On 27 September 2002, Dr Chris Moyses acquired 5,000 shares at a
      price of 150p. This increases Dr Moyses' holding to 31,876 ordinary
      shares, representing approximately 0.06% of the Company's issued
      share capital.

      On 26 September 2002, Mr Denis Mulhall was granted options over
      500,000 shares at an exercise price of 150p. The periods during
      which these options are exercisable are as follows:
      175,000 from 26 September 2005 to 25 September 2012;
      175,000 from 26 September 2007 to 25 September 2012;
      50,000 from 26 September 2004 to 25 September 2007;
      50,000 from 26 September 2005 to 25 September 2007; and
      50,000 from 26 September 2006 to 25 September 2007.

      J E Ilett
      Company Secretary
      27 September 2002